{"id":1394087,"date":"2021-07-31T18:21:13","date_gmt":"2021-07-31T16:21:13","guid":{"rendered":"https:\/\/finexsi.greenshift.eu\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/"},"modified":"2021-07-31T18:21:13","modified_gmt":"2021-07-31T16:21:13","slug":"finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen","status":"publish","type":"post","link":"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/","title":{"rendered":"Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A"},"content":{"rendered":"<p>Following off-market block purchases, a simplified tender offer and the subscription to a capital increase, CALLIDITAS THERAPEUTICS AB held 90.3% of the shares of GENKYOTEX SA, a biopharmaceutical company specialised in the development of NOX therapies. CALLIDITAS THERAPEUTICS AB therefore announced on July 28, 2021 its intention to launch a public withdrawal offer followed by a squeeze-out offer (\u00ab OPR-RO \u00bb) on the shares of GENKYOTEX SA.<\/p>\n<p>&nbsp;<\/p>\n<p>On the recommendation of the Ad Hoc Committee, the Board of Directors appointed on July 2, 2021 Finexsi as an independent expert to issue a report including a fairness opinion on the financial terms and conditions of the transaction. This fairness opinion was attached on July 8, 2021 to the note prepared in response to the public offer.<\/p>\n<p>&nbsp;<\/p>\n<p>The assignment was led by <a href=\"https:\/\/finexsi.eu\/en\/the-team-finexsi\/#Olivier_Courau\" target=\"_blank\" rel=\"noopener noreferrer\">Olivier Courau<\/a>, assisted by <a href=\"https:\/\/finexsi.eu\/en\/the-team-finexsi\/#Maxime_ROGEON\" target=\"_blank\" rel=\"noopener noreferrer\">Maxime Rogeon<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following off-market block purchases, a simplified tender offer and the subscription to a capital increase, CALLIDITAS THERAPEUTICS AB held 90.3% of the shares of GENKYOTEX SA, a biopharmaceutical company specialised in the development of NOX therapies. CALLIDITAS THERAPEUTICS AB therefore announced on July 28, 2021 its intention to launch a public withdrawal offer followed by [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[24],"tags":[40,45,32,35,44],"class_list":["post-1394087","post","type-post","status-publish","format-standard","hentry","category-news","tag-attestation-dequite","tag-fairness-opinion-en-3","tag-fairness-opinion","tag-fairness-opinion-en","tag-fairness-opinion-en-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A - Finexsi<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A - Finexsi\" \/>\n<meta property=\"og:description\" content=\"Following off-market block purchases, a simplified tender offer and the subscription to a capital increase, CALLIDITAS THERAPEUTICS AB held 90.3% of the shares of GENKYOTEX SA, a biopharmaceutical company specialised in the development of NOX therapies. CALLIDITAS THERAPEUTICS AB therefore announced on July 28, 2021 its intention to launch a public withdrawal offer followed by [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/\" \/>\n<meta property=\"og:site_name\" content=\"Finexsi\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-31T16:21:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/finexsi.eu\/wp-content\/uploads\/2024\/09\/finexsi.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Eddie Gins\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Eddie Gins\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/news\\\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/news\\\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\\\/\"},\"author\":{\"name\":\"Eddie Gins\",\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/#\\\/schema\\\/person\\\/a4238b407286e8d83c2c1a8d279390bd\"},\"headline\":\"Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A\",\"datePublished\":\"2021-07-31T16:21:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/news\\\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\\\/\"},\"wordCount\":162,\"publisher\":{\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/#organization\"},\"keywords\":[\"attestation d'\u00e9quit\u00e9\",\"fairness opinion\",\"fairness opinion\",\"fairness opinion\",\"fairness opinion\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/news\\\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\\\/\",\"url\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/news\\\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\\\/\",\"name\":\"Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A - Finexsi\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/#website\"},\"datePublished\":\"2021-07-31T16:21:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/news\\\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/finexsi.eu\\\/en\\\/news\\\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/news\\\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/\",\"name\":\"Finexsi\",\"description\":\"Fine Experts, Smart Solutions\",\"publisher\":{\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/#organization\"},\"alternateName\":\"Finexsi\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/#organization\",\"name\":\"Finexsi\",\"url\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/finexsi.eu\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/finexsi-logotype-cmjn-finexsi-logo-bleu-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/finexsi.eu\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/finexsi-logotype-cmjn-finexsi-logo-bleu-scaled.jpg\",\"width\":2560,\"height\":997,\"caption\":\"Finexsi\"},\"image\":{\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/finexsi\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/finexsi.eu\\\/en\\\/#\\\/schema\\\/person\\\/a4238b407286e8d83c2c1a8d279390bd\",\"name\":\"Eddie Gins\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/14eb2b2bbcd6d7dbd3540c2218722f0f5faa625847d1f2560ce22caf10b8f3e5?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/14eb2b2bbcd6d7dbd3540c2218722f0f5faa625847d1f2560ce22caf10b8f3e5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/14eb2b2bbcd6d7dbd3540c2218722f0f5faa625847d1f2560ce22caf10b8f3e5?s=96&d=mm&r=g\",\"caption\":\"Eddie Gins\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A - Finexsi","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/","og_locale":"en_US","og_type":"article","og_title":"Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A - Finexsi","og_description":"Following off-market block purchases, a simplified tender offer and the subscription to a capital increase, CALLIDITAS THERAPEUTICS AB held 90.3% of the shares of GENKYOTEX SA, a biopharmaceutical company specialised in the development of NOX therapies. CALLIDITAS THERAPEUTICS AB therefore announced on July 28, 2021 its intention to launch a public withdrawal offer followed by [&hellip;]","og_url":"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/","og_site_name":"Finexsi","article_published_time":"2021-07-31T16:21:13+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/finexsi.eu\/wp-content\/uploads\/2024\/09\/finexsi.jpg","type":"image\/jpeg"}],"author":"Eddie Gins","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Eddie Gins","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/#article","isPartOf":{"@id":"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/"},"author":{"name":"Eddie Gins","@id":"https:\/\/finexsi.eu\/en\/#\/schema\/person\/a4238b407286e8d83c2c1a8d279390bd"},"headline":"Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A","datePublished":"2021-07-31T16:21:13+00:00","mainEntityOfPage":{"@id":"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/"},"wordCount":162,"publisher":{"@id":"https:\/\/finexsi.eu\/en\/#organization"},"keywords":["attestation d'\u00e9quit\u00e9","fairness opinion","fairness opinion","fairness opinion","fairness opinion"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/","url":"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/","name":"Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A - Finexsi","isPartOf":{"@id":"https:\/\/finexsi.eu\/en\/#website"},"datePublished":"2021-07-31T16:21:13+00:00","breadcrumb":{"@id":"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/finexsi.eu\/en\/news\/finexsi-issued-its-report-as-an-independent-expert-in-connection-with-the-proposed-public-buy-out-offer-followed-by-a-squeeze-out-opr-ro-initiated-by-calliditas-therapeutics-ab-for-the-shares-of-gen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/finexsi.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A"}]},{"@type":"WebSite","@id":"https:\/\/finexsi.eu\/en\/#website","url":"https:\/\/finexsi.eu\/en\/","name":"Finexsi","description":"Fine Experts, Smart Solutions","publisher":{"@id":"https:\/\/finexsi.eu\/en\/#organization"},"alternateName":"Finexsi","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/finexsi.eu\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/finexsi.eu\/en\/#organization","name":"Finexsi","url":"https:\/\/finexsi.eu\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/finexsi.eu\/en\/#\/schema\/logo\/image\/","url":"https:\/\/finexsi.eu\/wp-content\/uploads\/2024\/09\/finexsi-logotype-cmjn-finexsi-logo-bleu-scaled.jpg","contentUrl":"https:\/\/finexsi.eu\/wp-content\/uploads\/2024\/09\/finexsi-logotype-cmjn-finexsi-logo-bleu-scaled.jpg","width":2560,"height":997,"caption":"Finexsi"},"image":{"@id":"https:\/\/finexsi.eu\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/finexsi"]},{"@type":"Person","@id":"https:\/\/finexsi.eu\/en\/#\/schema\/person\/a4238b407286e8d83c2c1a8d279390bd","name":"Eddie Gins","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/14eb2b2bbcd6d7dbd3540c2218722f0f5faa625847d1f2560ce22caf10b8f3e5?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/14eb2b2bbcd6d7dbd3540c2218722f0f5faa625847d1f2560ce22caf10b8f3e5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/14eb2b2bbcd6d7dbd3540c2218722f0f5faa625847d1f2560ce22caf10b8f3e5?s=96&d=mm&r=g","caption":"Eddie Gins"}}]}},"_links":{"self":[{"href":"https:\/\/finexsi.eu\/en\/wp-json\/wp\/v2\/posts\/1394087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finexsi.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finexsi.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/finexsi.eu\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/finexsi.eu\/en\/wp-json\/wp\/v2\/comments?post=1394087"}],"version-history":[{"count":0,"href":"https:\/\/finexsi.eu\/en\/wp-json\/wp\/v2\/posts\/1394087\/revisions"}],"wp:attachment":[{"href":"https:\/\/finexsi.eu\/en\/wp-json\/wp\/v2\/media?parent=1394087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finexsi.eu\/en\/wp-json\/wp\/v2\/categories?post=1394087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finexsi.eu\/en\/wp-json\/wp\/v2\/tags?post=1394087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}